What type of study is this?

Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States

View Full Paper

Ask AI

Bookmark

Patients prescribed vericiguat show a higher ejection fraction and fewer comorbid conditions compared to non-prescribed patients.
Notably, 62.3% of patients not prescribed vericiguat had hypertension, contrasting with 45.9% of those who were prescribed.
Analysis used logistic regression to explore prescription decisions among 228 heart failure patients in the U.S. during 2022-2023.
Identifying differences in demographics and health conditions may lead to improved strategies for prescribing vericiguat.

No takes yet. Share an insight, caveat, or question.

Cross-sectional analysis examines factors influencing vericiguat prescription in heart failure patients, indicating disparities.

Greene et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark